SLDB
Solid Biosciences Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsLast report1 of 5 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Solid Biosciences Inc.
Expected move
InputsLast report1 of 5 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Solid Biosciences Inc.
6.36
+0.08 · +1.26%
+18.81%
vs ±75.6% implied · ×0.25
shaded = implied · ▲▼ = realized
Bull3
Bear2
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $120.2M | 10.49% | +28.87% |
| Perceptive | $118.9M | 10.38% | 0.00% |
| Bain Capital Life Sciences Investors | $98.0M | 8.55% | 0.00% |
| Siren | $76.8M | 6.70% | 0.00% |
| BlackRockindex-like | $69.3M | 6.04% | +39.85% |
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $120.2M | 10.49% | +28.87% |
| Perceptive | $118.9M | 10.38% | 0.00% |
| Bain Capital Life Sciences Investors | $98.0M | 8.55% | 0.00% |
| Siren | $76.8M | 6.70% | 0.00% |
| BlackRockindex-like | $69.3M | 6.04% | +39.85% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Solid Biosciences Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Solid Biosciences Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
—
—
Expected move
No implied move.